IWP
JAZZ icon

Icon Wealth Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Icon Wealth Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-124
Closed -$21K – 501
2018
Q2 		$21K Buy
+124
New +$20.3K 0.01% 580

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Icon Wealth Partners's JAZZ Position: Q3 2018 in Review

Icon Wealth Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2018, closing a stake of 124 shares — an estimated $21K sold.

Icon Wealth Partners first reported a position in JAZZ in Q2 2018 and held it in 1 quarter. The position peaked at $21K in Q2 2018. 403 funds tracked by Wall St. Rank hold JAZZ as of Q3 2018.

  • Icon Wealth Partners reported no remaining Jazz Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Icon Wealth Partners sold 124 Jazz Pharmaceuticals shares in Q3 2018, an estimated $21K.
  • Icon Wealth Partners first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Icon Wealth Partners's Jazz Pharmaceuticals position peaked at $21K in Q2 2018.
  • 403 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2018.

Based on Icon Wealth Partners's 13F filing for Q3 2018, filed 14 Nov 2018.